晚期糖基化终末产物与肌少症的关联:骨质疏松的中介作用
这项横断面研究纳入1991名中国社区老年人(年龄72.37±5.90岁),采用AGE Reader测量晚期糖基化终末产物(AGEs)水平。结果显示AGEs最高四分位组与肌少症显著相关(OR 2.42;95%CI,1.60-3.66),AGEs每增加1个标准差,肌少症风险升高(OR 1.44;95%CI,1.26-1.66),且骨质疏松在AGEs与肌少症的关联中起部分中介作用。
要点
- AGEs最高四分位组与肌少症显著相关(OR 2.42;95%CI,1.60-3.66),但与肌少症前期无关。
- AGEs每增加1个标准差,肌少症风险升高(OR 1.44;95%CI,1.26-1.66)。
- 骨质疏松在AGEs与肌少症的关联中起部分中介作用(连续变量Zmediation效应95%CI,8.07-32.32;分类变量Zmediation=3.01>1.96)。
核心结论
- AGEs升高与肌少症相关,但与肌少症前期无关;这种关联部分由骨质疏松中介。
研究设计与样本
- 横断面研究,纳入1991名中国社区老年人,年龄72.37±5.90岁。
主要发现
- 肌少症患病率为18.5%,骨质疏松患病率为40.5%。
- 与AGEs最低四分位组相比,最高四分位组与肌少症显著相关(OR 2.42;95%CI,1.60-3.66),趋势P<.001,但与肌少症前期无关。
- AGEs每增加1个标准差,肌少症风险升高(OR 1.44;95%CI,1.26-1.66)。
- 中介分析中,AGEs作为连续变量时,中介效应Za*Zb=18.81(95%CI,8.07-32.32),95%CI不包含0,表示显著中介效应。
- AGEs作为分类变量时,中介效应Zmediation=3.01>1.96,表示显著中介效应;骨质疏松起部分中介作用。
关键数值与推荐
- 骨质疏松诊断依据T值小于-2.5。
- 肌少症定义为肌肉量减少加上肌肉力量下降和/或躯体功能减退。
- 肌少症前期定义为肌肉量低而肌肉力量和躯体功能正常。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Advanced glycation end products (AGEs) are a group of molecules formed through nonenzymatic reactions. These compounds are associated with several age-related diseases, including sarcopenia and osteoporosis. OBJECTIVE: This work aimed to investigate the relationships between AGEs, osteoporosis, and sarcopenia in community-dwelling older adults. METHODS: This cross-sectional study included 1991 older adults aged 72.37 ± 5.90 years from China. AGE levels were measured by the AGE Reader device. Bone mineral density was assessed using dual-energy X-ray absorptiometry, and osteoporosis was diagnosed based on a T score of less than -2.5. Sarcopenia was defined as loss of muscle mass plus loss of muscle strength and/or reduced physical performance. Presarcopenia was defined as low muscle mass with normal muscle strength and normal physical performance. RESULTS: The prevalence of sarcopenia was 18.5%, and that of osteoporosis was 40.5%. Compared to the lowest AGE quartile, the highest AGE quartile showed a significant association with sarcopenia (odds ratio [OR] 2.42; 95% CI, 1.60-3.66) (P for trend <.001), but not with presarcopenia. Per-SD increase in AGE was associated with higher odds of sarcopenia (OR 1.44; 95% CI, 1.26-1.66). Additionally, in the mediation analysis, when AGEs were treated as a continuous variable (the mediation effect is denoted by Za*Zb = 18.81; 95% CI, 8.07-32.32]-the 95% CI does not contain zero, representing a significant mediating effect) or a categorical variable (the mediating effect is expressed as Zmediation = 3.01 > 1.96, which represents a significant mediating effect), osteoporosis played a partial mediating role in the association between AGEs and sarcopenia. CONCLUSION: Elevated AGEs are associated with sarcopenia but not with presarcopenia. This association was partially mediated by osteoporosis.
引用
- Zhang X, Chen X, Li S, et al. Association Between Advanced Glycation End Products and Sarcopenia: The Mediating Role of Osteoporosis. J Clin Endocrinol Metab. 2024. PMID: 37925684. doi:10.1210/clinem/dgad640
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。